Abstract Number: 2527 • ACR Convergence 2023
Risk Factors for Bone Loss in Systemic Lupus Erythematosus
Background/Purpose: Osteoporotic fractures are the most common damage item from the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index. Previous…Abstract Number: 1072 • ACR Convergence 2023
Increase in Major Osteoporotic Fractures After Therapy with Immune Checkpoint Inhibitors
Background/Purpose: Immune checkpoint inhibitors (ICI) have revolutionized the treatment of cancer. Despite their efficacy on tumor outcomes they can cause severe and sometimes long-standing immune-related…Abstract Number: 2007 • ACR Convergence 2023
Effects of IL-17 Blockade on Skeletal Microarchitecture in Patients with Axial Spondyloarthritis: An HR-pQCT Study
Background/Purpose: Axial spondyloarthritis (AxSpA), a chronic inflammatory rheumatic disease causes abnormal bone growth at the spine and paradoxically has been linked to osteoporosis and fragility…Abstract Number: 2528 • ACR Convergence 2023
Current Trends in the Risk of Subsequent Fracture After Initial Fracture, and Post-Fracture Treatment Among Commercially Insured Postmenopausal Women in the United States
Background/Purpose: Recent studies suggest that post-fracture pharmacologic management has been declining in the U.S. despite an increase in the burden of osteoporosis (OP). In light…Abstract Number: 1098 • ACR Convergence 2023
Improving Osteoporosis Screening in Patients with Polymyalgia Rheumatica and Giant Cell Arteritis
Background/Purpose: Osteoporosis is a medical condition associated with decreased bone mass and bone architecture, which increases incidence of fragility fractures(4). It is associated with 1.5…Abstract Number: 2008 • ACR Convergence 2023
Comparative Effectiveness of Denosumab versus Alendronate Among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program
Background/Purpose: Although clinical trials have shown that denosumab (Dmab) significantly increases bone mineral density at key skeletal sites more than oral bisphosphonates, evidence is lacking…Abstract Number: 2529 • ACR Convergence 2023
Comparative Effectiveness of Denosumab versus Zoledronic Acid Among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program
Background/Purpose: Although clinical trials have shown that denosumab (Dmab) significantly increases bone mineral density at key skeletal sites more than zoledronic acid (ZA), evidence from…Abstract Number: 1620 • ACR Convergence 2023
Cardiovascular Risk and Fracture Risk Among Women Initiating Treatment with Romosozumab or Denosumab
Background/Purpose: Romosozumab (romo) and denosumab (dmab) are recommended for postmenopausal women with osteoporosis (OP) at high risk of fracture. The U.S. prescribing information includes a…Abstract Number: 2009 • ACR Convergence 2023
Screening and Treatment of Low Bone Mineral Density in Allogeneic Hematopoietic Cell Transplant Patients
Background/Purpose: Bone mineral density (BMD) loss and fracture are important causes of increased morbidity following allogeneic hematopoietic stem cell transplant (allo-HCT).Recent societal recommendations support screeningDual…Abstract Number: 2530 • ACR Convergence 2023
Risk Evaluation of Osteoporotic Fractures Following Lung Transplantation (LT): A Retrospective Cohort Study Conducted at an International Transplant Center
Background/Purpose: Osteoporotic fractures are a well-known complication in LT recipients, significantly impacting their quality of life. Specific risk factors for these fractures in LT recipients…Abstract Number: 1719 • ACR Convergence 2023
Exploring the Link Between Osteitis and Bone Microstructure Changes in Rheumatoid Arthritis: Role of JAK-STAT Signaling Pathway
Background/Purpose: Osteitis on MRI and bone microstructure changes (BMC) on high-resolution peripheral quantitative CT are the earliest signs of arthritis, preceding the development of bone…Abstract Number: 2010 • ACR Convergence 2023
B-FROST: Chronic OBstructive Pulmonary Disease and Vertebral FRacture of OSTeoporotic Origin: Results of a Real-life Cohort
Background/Purpose: Chronic obstructive pulmonary disease (COPD) is a chronic disease of the airways. It is mainly caused by smoking. Active smoking is a risk factor…Abstract Number: 2531 • ACR Convergence 2023
Proton Pump Inhibitor Use Is Associated with Impaired Bone Mineral Density but Not Bone Microarchitecture in Patients with Inflammatory Rheumatic and Musculoskeletal Diseases Taking Glucocorticoids
Background/Purpose: Patients with inflammatory rheumatic and musculoskeletal diseases (iRMDs) are at increased risk of osteoporosis and fragility fractures. For this population, whether proton pump inhibitor…Abstract Number: 1818 • ACR Convergence 2023
Compliance with Romosozumab and Fracture Risk Among Postmenopausal Women in the U.S
Background/Purpose: Romosozumab (romo) is a newly approved osteoporosis (OP) medicine for women with postmenopausal OP at high risk of fracture. The utilization pattern of romo…Abstract Number: 2011 • ACR Convergence 2023
Predicting Fractures in Patients with Isolated Lumbar Spine Osteoporosis Compared to Those with Isolated Hip Osteoporosis
Background/Purpose: Osteoporosis (OP) presents with fragility fractures, which can cause significant disability and cost to health services globally. There has been extensive research looking at…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 20
- Next Page »